[Correspondence] Proton-pump inhibitors and glecaprevir plus pibrentasvir in HCV infection

Drug interactions between proton-pump inhibitors and direct-acting antiviral drugs are a great concern in patients with hepatitis C virus infection, because of the potential for suboptimal plasma concentrations of direct-acting antiviral drugs leading to compromised outcomes.1,2 In the phase 3 trial reported by Xavier Forns and colleagues,3 31 (21%) patients with hepatitis C virus infection and compensated cirrhosis receiving glecaprevir plus pibrentasvir were concurrently treated with proton-pump inhibitors.

from ! ORL Sfakianakis via paythelady.61 on Inoreader http://ift.tt/2mUDqxp
via IFTTT